2,2'-disulfanediyl-bis-imidazole-1-carboxylic acid diethyl ester | 105540-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,2'-disulfanediyl-bis-imidazole-1-carboxylic acid diethyl ester
• 英文别名: 2,2'-Disulfandiyl-bis-imidazol-1-carbonsaeure-diaethylester；Ethyl 2-[(1-ethoxycarbonylimidazol-2-yl)disulfanyl]imidazole-1-carboxylate；ethyl 2-[(1-ethoxycarbonylimidazol-2-yl)disulfanyl]imidazole-1-carboxylate
• CAS: 105540-32-7
• 化学式: C₁₂H₁₄N₄O₄S₂
• 分子量: 342.4
• InChiKey: XBXPMGRYNAONGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  139
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  neral 在 硝酸 、 溶剂黄146 作用下， 生成 2,2'-disulfanediyl-bis-imidazole-1-carboxylic acid diethyl ester
  参考文献：
  名称：

  230. 2-巯基乙二酸。第十部分2-巯基乙二醛的酰化作用

  摘要：

  DOI：

  10.1039/jr9560001103

文献信息

• NANOPARTICLE, LIPOSOMES, POLYMERS, AGENTS AND PROTEINS MODIFIED WITH REVERSIBLE LINKERS
  申请人：DeSimone Joseph M.

  公开号：US20140081012A1

  公开（公告）日：2014-03-20

  Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain an agent having a reversible disulfide linker and to vehicles that are covalently linked to the agent containing a reversible disulfide linker. The modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting while the reversibility of the linker can leave the agent to which it is attached free from residual chemical groups after being reduced.

  本文描述了含有可逆二硫键连接剂的制药、化学和生物制剂。这些制剂也可以共价结合或包含在传递载体中，以将制剂传递到所需的目标或区域。还描述了包含具有可逆二硫键连接剂的制剂的传递载体，以及与含有可逆二硫键连接剂的制剂共价链接的载体。本文所描述的修饰可以修改制剂和载体的性质，从而提供所需的溶解度、稳定性、疏水性和定向性，而连接剂的可逆性可以使其附着的制剂在还原后不留下残留的化学基团。
• [EN] MULTI-CONJUGATES COMPRISING A MONO-SUBSTITUTED HOMO-BIVALENT LINKER<br/>[FR] MULTI-CONJUGUÉS COMPRENANT UN LIEUR HOMOBIVALENT MONO-SUBSTITUÉ
  申请人：MPEG LA L L C

  公开号：WO2022081894A1

  公开（公告）日：2022-04-21

  Various embodiments provide a homo-bivalent covalent linker substituted on one end by a substituent X, wherein X comprises a biological moiety other than a nucleic acid.

  各种实施例提供了一种同源双价共价连接剂，其一端被取代基X取代，其中X包括除核酸以外的生物基团。
• Method of treating cancer with a biomaterial and a toll-like receptor agonist
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10413612B2

  公开（公告）日：2019-09-17

  Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.

  本文提供了用于治疗和/或预防癌症和转移性肿瘤的给药组合物和装置。例如，提供了一种药物输送装置，它包括一种可生物降解的支架，其中携带一种或多种激活先天性免疫系统（如 STING 激动剂）和/或适应性免疫系统（如抗 PD-1 抗体）的抗癌治疗剂。组合物和装置可包括细胞因子（如 IL-15 超拮抗剂）。该给药装置可植入切除肿瘤的空隙中，以防止肿瘤再生和肿瘤转移。此外，还提供了制造给药组合物和装置的方法，以及含有提供组合物和装置的材料的试剂盒。
• Drug delivery compositions and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10435469B2

  公开（公告）日：2019-10-08

  Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.

  本文提供了用于治疗和/或预防癌症和转移性肿瘤的给药组合物和装置。例如，提供了一种药物输送装置，它包括一种可生物降解的支架，其中携带一种或多种激活先天性免疫系统（如 STING 激动剂）和/或适应性免疫系统（如抗 PD-1 抗体）的抗癌治疗剂。组合物和装置可包括细胞因子（如 IL-15 超拮抗剂）。该给药装置可植入切除肿瘤的空隙中，以防止肿瘤再生和肿瘤转移。此外，还提供了制造给药组合物和装置的方法，以及含有提供组合物和装置的材料的试剂盒。
• Multimeric oligonucleotides having decreased kidney clearance
  申请人：MPEG LA, LLC

  公开号：US11078484B2

  公开（公告）日：2021-08-03

  The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.

  本发明涉及向受试者施用具有通过连接体连接的单体亚基的多聚物寡核苷酸的方法。这些多聚物寡核苷酸的分子量至少约为 45 kD，并具有其他特征，从而减少了它们因肾小球滤过而产生的清除率。本发明还涉及这种多聚物寡核苷酸和合成这种多聚物寡核苷酸的方法。